JP4261050B2 - ヒト・チェックポイントキナーゼｈｃｄｓ１の組成物および方法 - Google Patents

ヒト・チェックポイントキナーゼｈｃｄｓ１の組成物および方法 Download PDF

Info

Publication number
JP4261050B2
JP4261050B2 JP2000521208A JP2000521208A JP4261050B2 JP 4261050 B2 JP4261050 B2 JP 4261050B2 JP 2000521208 A JP2000521208 A JP 2000521208A JP 2000521208 A JP2000521208 A JP 2000521208A JP 4261050 B2 JP4261050 B2 JP 4261050B2
Authority
JP
Japan
Prior art keywords
protein
hcds1
acid sequence
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000521208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001523461A (ja
Inventor
ライテン，ワルター・ハー・エム・エル
パーカー，アンドリユー・イー
マゴーアン，クレア
ブラシーナ，アレツサンドラ
Original Assignee
ザ・スクリプス・リサーチ・インステイチユート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・スクリプス・リサーチ・インステイチユート filed Critical ザ・スクリプス・リサーチ・インステイチユート
Publication of JP2001523461A publication Critical patent/JP2001523461A/ja
Application granted granted Critical
Publication of JP4261050B2 publication Critical patent/JP4261050B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000521208A 1997-10-22 1998-10-21 ヒト・チェックポイントキナーゼｈｃｄｓ１の組成物および方法 Expired - Fee Related JP4261050B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9722320.0A GB9722320D0 (en) 1997-10-22 1997-10-22 Human cell cycle checkpoint proteins
GB9722320.0 1997-10-22
PCT/EP1998/006981 WO1999025843A2 (en) 1997-10-22 1998-10-21 Human checkpoint kinase, hcds1, compositions and methods

Publications (2)

Publication Number Publication Date
JP2001523461A JP2001523461A (ja) 2001-11-27
JP4261050B2 true JP4261050B2 (ja) 2009-04-30

Family

ID=10820925

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000521208A Expired - Fee Related JP4261050B2 (ja) 1997-10-22 1998-10-21 ヒト・チェックポイントキナーゼｈｃｄｓ１の組成物および方法
JP2000517068A Expired - Lifetime JP4418103B2 (ja) 1997-10-22 1998-10-21 新規なヒトチェックポイントキナーゼ、ｈＣＤＳ１、組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2000517068A Expired - Lifetime JP4418103B2 (ja) 1997-10-22 1998-10-21 新規なヒトチェックポイントキナーゼ、ｈＣＤＳ１、組成物および方法

Country Status (13)

Country Link
US (4) US6531312B1 (enExample)
EP (2) EP1025237B1 (enExample)
JP (2) JP4261050B2 (enExample)
AT (2) ATE300619T1 (enExample)
AU (2) AU760544B2 (enExample)
CA (2) CA2308013A1 (enExample)
DE (2) DE69831500T2 (enExample)
DK (2) DK1025237T3 (enExample)
ES (2) ES2245050T3 (enExample)
GB (1) GB9722320D0 (enExample)
IL (2) IL135687A (enExample)
NZ (2) NZ503983A (enExample)
WO (2) WO1999025843A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) * 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
CA2331152A1 (en) * 1998-06-23 1999-12-29 Chugai Seiyaku Kabushiki Kaisha Cell cycle regulating factor
GB9827430D0 (en) * 1998-12-11 1999-02-03 Ludwig Inst Cancer Res Differential expression in primary breast cancer
CA2400785A1 (en) * 2000-02-18 2001-08-23 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
AU2001237599A1 (en) * 2000-03-08 2001-09-17 Zealand Pharma A/S Materials and methods relating to the degradation of cdc25a in response to dna damage
CA2406399A1 (en) * 2000-04-20 2001-11-01 Incyte Genomics, Inc. Human kinases
US6323016B1 (en) 2000-06-09 2001-11-27 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
FR2812945B1 (fr) * 2000-08-10 2002-10-04 Aventis Pharma Sa Utilisation de la proteine grf1 et cellules exprimant la proteine grf1 pour le criblage de molecules
US6372468B1 (en) * 2000-09-14 2002-04-16 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2002211305A1 (en) * 2000-12-14 2002-06-24 Pe Corporation (Ny) Isolated human kinase proteins, their encoding nucleic acid molecules, and uses thereof
WO2002051858A2 (en) * 2000-12-22 2002-07-04 Isis Pharmaceuticals, Inc. Antisense modulation of chk2 expression
US6451538B1 (en) * 2000-12-22 2002-09-17 Isis Pharmaceuticals, Inc. Antisense modulation of CHK2 expression
WO2002059325A2 (en) * 2000-12-27 2002-08-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
EP1224942A1 (en) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP1947102A1 (en) * 2003-01-09 2008-07-23 Pfizer, Inc. Compositions comprising diazepinoindole derivatives as kinase inhibitors
EP1660503A1 (en) * 2003-08-29 2006-05-31 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
WO2005021554A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
US8572169B2 (en) * 2006-08-28 2013-10-29 Myspace, Llc System, apparatus and method for discovery of music within a social network
MX2009012054A (es) 2007-05-08 2009-11-19 Schering Corp Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida.
CA2731368C (en) * 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5674748A (en) * 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
PL322876A1 (en) * 1995-11-16 1998-03-02 Icos Corp Pik type kinase of cellular cycle control point: materials and methods
US5744349A (en) * 1996-03-05 1998-04-28 Washington University DNA sequences encoding human Myt1 kinase
US6218109B1 (en) * 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9722320D0 (en) * 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins

Also Published As

Publication number Publication date
WO1999020747A3 (en) 1999-07-01
CA2306492A1 (en) 1999-05-27
IL135687A (en) 2007-07-04
WO1999025843A3 (en) 1999-08-05
US6943013B2 (en) 2005-09-13
AU1232299A (en) 1999-05-10
DK1025237T3 (da) 2005-11-28
DE69831500T2 (de) 2006-06-14
EP1025236B1 (en) 2005-07-27
IL135688A0 (en) 2001-05-20
JP4418103B2 (ja) 2010-02-17
WO1999025843A2 (en) 1999-05-27
US6531312B1 (en) 2003-03-11
EP1025237B1 (en) 2005-09-07
EP1025236A2 (en) 2000-08-09
ATE304052T1 (de) 2005-09-15
NZ503965A (en) 2002-03-28
DE69831007T2 (de) 2006-04-20
US7414020B2 (en) 2008-08-19
DE69831007D1 (de) 2005-09-01
GB9722320D0 (en) 1997-12-17
ES2245050T3 (es) 2005-12-16
AU752617B2 (en) 2002-09-26
ES2245807T3 (es) 2006-01-16
US20050180981A1 (en) 2005-08-18
AU2612699A (en) 1999-06-07
US20030017160A1 (en) 2003-01-23
DE69831500D1 (de) 2005-10-13
JP2001523461A (ja) 2001-11-27
CA2308013A1 (en) 1999-04-29
IL135687A0 (en) 2001-05-20
JP2001520037A (ja) 2001-10-30
CA2306492C (en) 2014-03-25
EP1025237A2 (en) 2000-08-09
AU760544B2 (en) 2003-05-15
WO1999020747A2 (en) 1999-04-29
ATE300619T1 (de) 2005-08-15
IL135688A (en) 2010-04-29
NZ503983A (en) 2002-03-28
DK1025236T3 (da) 2005-10-24
US6413755B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
JP4261050B2 (ja) ヒト・チェックポイントキナーゼｈｃｄｓ１の組成物および方法
US5756289A (en) Protein kinases
US20030050230A1 (en) Ste20-related protein kinases
US7202049B2 (en) Mitogen-activated protein kinase p38-2 and methods of use therefor
US6586242B1 (en) TAO protein kinases and methods of use therefor
US5830699A (en) SOK-1 and methods of use
AU2003235055B2 (en) Human checkpoint kinase, HCDS1, compositions and methods
EP1214453B1 (en) Novel cell cycle checkpoint genes and proteins encoded thereby
US7241585B2 (en) 14171 protein kinase, a novel human protein kinase and uses thereof
EP0997537A2 (en) Assay for detecting modulators of serine/threonine phosphatease activity
US7078182B1 (en) TAO protein kinase polypeptides and methods of use therefor
EP1090987A1 (en) Cell cycle regulatory factor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081001

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090120

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090205

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120220

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120220

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140220

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees